Although EZH2 inhibitors (EZH2i) have shown promise in preclinical studies (Gulati et al, 2018; McCabe et al, 2012; Miranda et al, 2009; Verma et al, 2012), they have had modest anticancer activity as a monotherapy in PCa (Yap et al, 2019). Here, EZH2 is linked to posterior cortical atrophy.